Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study
Cardiorenal Medicine · 22.01.2026 · 16 (1) · 58-67
DOI: 10.1159/000550521 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiorenal Medicine, online erschienen am 22.01.2026. Verfasst von Wei-Chiao Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Ticagrelor, Clopidogrel, Myocardial Infarction, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Chronic kidney disease (CKD) is a major risk factor for cardiovascular morbidity and mortality, particularly in patients with acute myocardial infarction (AMI). Dual antiplatelet therapy is essential for secondary prevention in AMI, but the optimal P2Y12 inhibitor in CKD patients remains unclear. While ticagrelor has demonstrated superior cardiovascular outcomes compared to clopidogrel in the general population, its safety and efficacy in advanced CKD are not well established.
Methods
This retrospective cohort study analyzed data from the Chang Gung Research Database (CGRD) to compare ticagrelor and clopidogrel in CKD stage III–V patients hospitalized with AMI between 2001 and 2020. Inverse probability of treatment weighting was applied to balance baseline characteristics. Clinical outcomes, including recurrent AMI, ischemic stroke, cardiovascular death, major bleeding events, and all-cause mortality, were evaluated using Cox proportional hazards models and competing risk analysis.
Results
Among 3,461 patients (ticagrelor: 704, clopidogrel: 2,757), ticagrelor was associated with a significantly lower risk of all-cause mortality (HR 0.694, 95% CI 0.539–0.894, p = 0.047), with no significant differences in recurrent AMI, ischemic stroke, cardiovascular death, or major bleeding events.
Conclusions
In CKD patients with AMI, ticagrelor was associated with reduced all-cause mortality compared to clopidogrel, without an increased risk of major bleeding. These findings highlight the need for further prospective studies to confirm ticagrelor’s benefits and inform optimal antiplatelet strategies in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
- Kidney Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
- Division of Cardiology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital, New Taipei City, Taiwan.
- Center for Artificial Intelligence in Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.
Zitieren
APA
Sun, W. C., Lee, H. F., Lin, C., Huang, S. C., Chen, J. J., Ho, W. Y., Yen, C. L., & Hsiao, C. C. (2026). Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study. Cardiorenal Medicine, 16(1), 58-67. https://doi.org/10.1159/000550521
Vancouver
Sun WC, Lee HF, Lin C, Huang SC, Chen JJ, Ho WY, et al. Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study. Cardiorenal Medicine. 2026;16(1):58-67. doi:10.1159/000550521
BibTeX
@article{Sun2026,
author = {Sun, Wei-Chiao and Lee, Hsin-Fu and Lin, Chihung and Huang, Shu-Chun and Chen, Jia-Jin and Ho, Wen-Yu and Yen, Chieh-Li and Hsiao, Ching-Chung},
title = {Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study},
journal = {Cardiorenal Medicine},
year = {2026},
volume = {16},
number = {1},
pages = {58--67},
doi = {10.1159/000550521}
}
EUVIMED